Facebook
Twitter
Telegram
Report an ErrorSQZ Biotechnologies Company Balance Sheet 2011-2024 | SQZ
Annual Balance Sheet SQZ Biotechnologies Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36.2 M | -73.8 M | -123 M | 3.08 M | -59.6 M | - | - | - | - | - | - | - |
Long Term Debt |
20.9 M | 59.8 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
6.56 M | 9.94 M | 8.21 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 58.7 M | 188 M | 138 M | - | - | - | - | - | - | - |
Total Current Liabilities |
21.8 M | 33.2 M | 45.2 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
42.8 M | 102 M | 104 M | 226 M | 159 M | - | - | - | - | - | - | - |
Deferred Revenue |
715 K | 12.5 M | 25.9 M | 19 M | 16.5 M | - | - | - | - | - | - | - |
Retained Earnings |
-275 M | -196 M | -127 M | -76.2 M | -44 M | - | - | - | - | - | - | - |
Total Assets |
99.9 M | 226 M | 231 M | 152 M | 116 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
63.7 M | 144 M | 170 M | 41.6 M | - | - | - | - | - | - | - | - |
Book Value |
57.1 M | 124 M | 127 M | -73.5 M | -43.5 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
57.1 M | 124 M | 127 M | -73.5 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet SQZ Biotechnologies Company
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19.1 M | 19.7 M | 20.3 M | 20.9 M | 51.8 M | - | 57.2 M | 59.8 M | 62.4 M | 32.6 M | 36.4 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 32.9 M | 32.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
27.9 M | 29.6 M | 33 M | 42.8 M | 86.3 M | - | 95.9 M | 102 M | 111 M | 85.8 M | 93.6 M | 104 M | 104 M | 104 M | 104 M | 93.8 M | 93.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 500 K | 678 K | 715 K | 3.5 M | - | 9.64 M | 12.5 M | 21.9 M | 26.6 M | 25.5 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 19 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-333 M | -309 M | -293 M | -275 M | -261 M | - | -217 M | -196 M | -184 M | -161 M | -142 M | -127 M | -127 M | -127 M | -127 M | -76.2 M | -76.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
29.8 M | 54.1 M | 73.2 M | 99.9 M | 155 M | - | 201 M | 226 M | 244 M | 239 M | 263 M | 231 M | 231 M | 231 M | 231 M | 152 M | 152 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.2 M | 24.7 M | 39.9 M | 63.7 M | 86.5 M | 108 M | 125 M | 144 M | 167 M | 185 M | 205 M | 170 M | 170 M | 170 M | 170 M | 39.3 M | 39.3 M | - | - | 61.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.88 M | 24.5 M | 40.2 M | 57.1 M | 68.6 M | - | 105 M | 124 M | 133 M | 153 M | 169 M | 127 M | 127 M | 127 M | 127 M | 58.6 M | 58.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.88 M | 24.5 M | 40.2 M | 57.1 M | 68.6 M | 88.2 M | 105 M | 124 M | 133 M | 153 M | 169 M | 127 M | 127 M | 127 M | 127 M | -73.5 M | -73.5 M | -56.5 M | - | -43.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency